KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Assets: 2010-2024

Historic Current Assets for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $745.1 million.

  • Pacira BioSciences' Current Assets fell 18.44% to $562.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.8 million, marking a year-over-year decrease of 18.44%. This contributed to the annual value of $745.1 million for FY2024, which is 46.11% up from last year.
  • As of FY2024, Pacira BioSciences' Current Assets stood at $745.1 million, which was up 46.11% from $510.0 million recorded in FY2023.
  • Over the past 5 years, Pacira BioSciences' Current Assets peaked at $866.0 million during FY2021, and registered a low of $498.3 million during FY2022.
  • Over the past 3 years, Pacira BioSciences' median Current Assets value was $510.0 million (recorded in 2023), while the average stood at $584.5 million.
  • As far as peak fluctuations go, Pacira BioSciences' Current Assets surged by 59.49% in 2020, and later tumbled by 42.46% in 2022.
  • Yearly analysis of 5 years shows Pacira BioSciences' Current Assets stood at $651.6 million in 2020, then surged by 32.91% to $866.0 million in 2021, then crashed by 42.46% to $498.3 million in 2022, then rose by 2.34% to $510.0 million in 2023, then spiked by 46.11% to $745.1 million in 2024.